# 60 Degrees Pharmaceuticals Inc. (SXTP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $2M  
**Price:** $1.38 (-0.72%)

> 60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing medicines for the treatment and prevention of vector-borne and infectious diseases. Its primary product, ARAKODA (tafenoquine), is an FDA-approved antimalarial for malaria prophylaxis in adults 18 years and older, featuring a dosing regimen with a loading phase, weekly doses during exposure, and a final dose post-travel, available through prescription in the United States and Australia as KODATEF. The company sponsors clinical trials exploring tafenoquine for babesiosis, a tick-borne parasitic illness, including studies on relapsing, hospitalized, and chronic cases, addressing unmet needs where no specific FDA-approved treatments exist. 60 Degrees Pharmaceuticals Inc. also pursues research into other vector-borne conditions like those linked to Lyme disease pathogens through collaborations with academic institutions in the United States, Australia, and Singapore. Founded in 2010 and headquartered in Washington, D.C., with research and development in Australia, it operates in the pharmaceuticals and biotechnology sector, emphasizing tafenoquine-based therapies for diseases transmitted by mosquitoes and ticks.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | $223,776 | -$8M | -$7M | $-11.73 |
| 2024 | $607,574 | $222,809 | -$10M | -$8M | $-74.20 |
| 2023 | $253,573 | -$220,977 | -$5M | -$4M | $-11.88 |
| 2022 | $223,208 | -$209,162 | -$2M | -$6M | $-13.32 |
| 2021 | $1M | $309,598 | -$1M | -$4M | $-9.16 |
| 2020 | $2M | $1M | -$368,914 | -$3M | $-6.54 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $5M | $2M | $3M | $2M | $144,003 |
| 2024 | $6M | $2M | $4M | $2M | $147,119 |
| 2023 | $8M | $3M | $5M | $2M | $150,251 |
| 2022 | $1M | $25M | -$24M | $264,865 | $1M |
| 2021 | $1M | $20M | -$18M | $115,399 | $19M |
| 2020 | $3M | $21M | -$18M | $191,702 | $16M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$7M | -$139,881 | -$7M |
| 2024 | -$4M | -$103,773 | -$6M |
| 2023 | -$7M | -$57,623 | -$5M |
| 2022 | -$4M | — | -$1M |
| 2021 | -$3M | -$3,068 | -$684,498 |
| 2020 | -$2M | — | -$238,277 |

Source: [CompaniesByCap](https://companiesbycap.com/company/SXTP)